Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow mononuclear cells (Cedars-Sinai)
- Development stage
- Unknown
- Lead developer
- Cedars-Sinai
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intracoronary
01
Overview
Autologous bone marrow mononuclear cells (BMMNCs) are a cell therapy product consisting of a mixture of stem and progenitor cells derived from the patient's own bone marrow. Developed by Cedars-Sinai Medical Center for the treatment of acute myocardial infarction, the therapy involves harvesting bone marrow, isolating the mononuclear fraction, and delivering the cells via intracoronary injection into the infarct-related artery shortly after a heart attack. The mechanism of action is thought to involve paracrine signaling that promotes angiogenesis, reduces apoptosis, and potentially contributes to myocardial regeneration, with the ultimate goal of improving cardiac function and preventing heart failure.
- Other names
- autologous bone marrow-derived mononuclear cellsintracoronary transplantation of bone marrow stem cellsintracoronary autologous bone marrow mononuclear cells
Beyond the preview
Go deeper on autologous bone marrow mononuclear cells (Cedars-Sinai).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow mononuclear cells (Cedars-Sinai).